[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Organon & Co. (OGN)

Organon & Co. (OGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,505,724
  • Shares Outstanding, K 262,601
  • Annual Sales, $ 6,216 M
  • Annual Income, $ 187,000 K
  • EBIT $ 892 M
  • EBITDA $ 1,737 M
  • 60-Month Beta 1.57
  • Price/Sales 0.56
  • Price/Cash Flow 2.30
  • Price/Book 3.87

Options Overview Details

View History
  • Implied Volatility 20.55% (+7.34%)
  • Historical Volatility 126.17%
  • IV Percentile 2%
  • IV Rank 5.43%
  • IV High 148.31% on 03/20/26
  • IV Low 13.22% on 05/07/26
  • Expected Move (DTE 6) 0.33 (2.48%)
  • Put/Call Vol Ratio 4.58
  • Today's Volume 2,231
  • Volume Avg (30-Day) 19,662
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 222,802
  • Open Int (30-Day) 174,150
  • Expected Range 13.02 to 13.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.85
  • Number of Estimates 2
  • High Estimate $0.87
  • Low Estimate $0.83
  • Prior Year $0.94
  • Growth Rate Est. (year over year) -9.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.82 +129.38%
on 04/09/26
13.44 -0.67%
on 05/06/26
+7.49 (+127.82%)
since 04/08/26
3-Month
5.69 +134.62%
on 03/30/26
13.44 -0.67%
on 05/06/26
+5.14 (+62.61%)
since 02/06/26
52-Week
5.69 +134.62%
on 03/30/26
13.44 -0.67%
on 05/06/26
+4.33 (+48.00%)
since 05/08/25

Most Recent Stories

More News
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX

NEW YORK , May 6, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

XOMA : 41.89 (+1.45%)
RMAX : 10.38 (-6.15%)
HLX : 9.66 (-1.73%)
OGN : 13.35 (+0.23%)
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

TBRG : 25.83 (+0.19%)
OGN : 13.35 (+0.23%)
CYCN : 3.10 (-1.59%)
Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates

Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates

OGN : 13.35 (+0.23%)
Organon: Q1 Earnings Snapshot

Organon: Q1 Earnings Snapshot

OGN : 13.35 (+0.23%)
Organon Reports Results for the First Quarter Ended March 31, 2026

First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and non-GAAP...

OGN : 13.35 (+0.23%)
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

SHANGHAI , April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY...

OGN : 13.35 (+0.23%)
Organon Cancels First Quarter Earnings Call

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings...

OGN : 13.35 (+0.23%)
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY ® (pertuzumab) 420 mg/14 mL...

OGN : 13.35 (+0.23%)
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Organon & Co. ...

OGN : 13.35 (+0.23%)
Nasdaq Futures Plunge as AI Concerns Resurface, FOMC Meeting and Earnings in Focus

June Nasdaq 100 E-Mini futures (NQM26) are trending down -1.24% this morning as concerns resurfaced over whether the massive amounts of investment in AI will ultimately pay off.

NVDA : 215.20 (+1.75%)
GOOGL : 400.80 (+0.71%)
NOVN.Z.IX : 113.340 (-0.42%)
AVGO : 430.00 (+4.23%)
SNDK : 1,562.34 (+16.60%)
KO : 78.42 (-0.01%)
BBBY : 5.30 (-1.12%)
ORCL : 195.95 (+0.70%)
RMBS : 129.24 (+2.09%)
TEL.O.DX : 154.450 (+0.03%)
BP-.LN : 535.900 (-0.30%)
TMUS : 193.63 (-0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Organon is a healthcare company. It focuses on the health of women throughout their lives. Organon is based in JERSEY CITY, N.J.

See More

Key Turning Points

3rd Resistance Point 13.47
2nd Resistance Point 13.42
1st Resistance Point 13.38
Last Price 13.35
1st Support Level 13.30
2nd Support Level 13.25
3rd Support Level 13.21

See More

52-Week High 13.44
Last Price 13.35
Fibonacci 61.8% 10.48
Fibonacci 50% 9.56
Fibonacci 38.2% 8.65
52-Week Low 5.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.